The drugmaker released its second-quarter earnings report early Wednesday as it vowed to cut costs amid intensifying ...

The FDA says shortages of GLP-1s are over, but many patients are still getting what are essentially copied medications.

No difference in mortality risk seen for GLP-1 RA and SGLT2i users; significantly lower risk seen for GLP-1 RA versus DPP4i users.

For older adults with type 2 diabetes, GLP-1 RA use is associated with nonarteritic anterior ischemic optic neuropathy.

The tech trade is proving resilient, even unstoppable, while the firms that gained by helping people lose weight are ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second quarter ...

In the second part of his Pharma Commerce video interview, Philip Sclafani, PwC's pharmaceutical and life sciences lead, ...

Novo Nordisk reported second quarter earnings a week after revising its 2025 outlook down on slower GLP-1 sales.

Receive a weekly dose of discovery in your inbox. We'll also keep you up to date with New Scientist events and special offers. Download the app ...

I’ve had a very eventful year. At the beginning of 2025, my long-term relationship ended, and after a few months, I decided ...

Novo Nordisk is to cut costs as the Wegovy-maker battles competition from rival Eli Lilly and copycat versions of its obesity ...

The Milwaukee Bucks Health and Wellness program is celebrating its one-year anniversary. The free medical program was ...